---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-029341"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:26:45.398459+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Palvella makes corporate presentation available; no new specifics disclosed

## Summary
- Presentation titled 'First-in-disease therapies for rare diseases' dated January 2026.
- No financial results, clinical data, or guidance changes included in the provided excerpt.
- Filing does not contain material new information beyond the presentation's availability.

## SEC filing metadata
- accession: 0001193125-26-029341
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000119312526029341/0001193125-26-029341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000119312526029341/pvla-20260129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-029341
- JSON: https://secwatch.observer/filing/0001193125-26-029341.json
- Plain text: https://secwatch.observer/filing/0001193125-26-029341.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.